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The emergence of antimicrobial resistance severely threatens our ability to treat
bacterial infections. While acquired resistance has received considerable attention,
relatively little is known of intrinsic resistance that allows bacteria to naturally withstand
antimicrobials. Gene products that confer intrinsic resistance to antimicrobial agents
may be explored for alternative antimicrobial therapies, by potentiating the efficacy
of existing antimicrobials. In this study, we identified the intrinsic resistome to a
broad spectrum of antimicrobials in the human pathogen, Staphylococcus aureus. We
screened the Nebraska Transposon Mutant Library of 1920 single-gene inactivations
in S. aureus strain JE2, for increased susceptibility to the anti-staphylococcal
antimicrobials (ciprofloxacin, oxacillin, linezolid, fosfomycin, daptomycin, mupirocin,
vancomycin, and gentamicin). Sixty-eight mutants were confirmed by E-test to display at
least twofold increased susceptibility to one or more antimicrobial agents. The majority of
the identified genes have not previously been associated with antimicrobial susceptibility
in S. aureus. For example, inactivation of genes encoding for subunits of the ATP
synthase, atpA, atpB, atpG and atpH, reduced the minimum inhibitory concentration
(MIC) of gentamicin 16-fold. To elucidate the potential of the screen, we examined
treatment efficacy in the Galleria mellonella infection model. Gentamicin efficacy was
significantly improved, when treating larvae infected with the atpA mutant compared
to wild type cells with gentamicin at a clinically relevant concentration. Our results
demonstrate that many gene products contribute to the intrinsic antimicrobial resistance
of S. aureus. Knowledge of these intrinsic resistance determinants provides alternative
targets for compounds that may potentiate the efficacy of existing antimicrobial agents
against this important pathogen.
Keywords: Staphylococcus aureus, antimicrobial agents, intrinsic resistance, potentiator targets, Galleria
mellonella
INTRODUCTION
Antibiotic resistant bacteria are a growing global issue that reduces our ability to cure bacterial
infections (Gould, 2009; Davies and Davies, 2010). The limited success in identifying promising
new antimicrobial entities led to a search for new approaches to counter the increasing problems
of antibiotic resistance (Butler et al., 2013). One approach suggested is to re-sensitize resistant
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bacteria to an antimicrobial agent by potentiating the efficacy
of an antimicrobial with a helper-drug. The helper-drug can
target gene products that by any mechanism aid bacteria to resist
higher concentrations of an antimicrobial (Pieren and Tigges,
2012). Besides the ability of bacteria to acquire antimicrobial
resistance via horizontal gene transfer or spontaneous mutations,
they can also be intrinsically resistant to antimicrobials (Cox
and Wright, 2013). Intrinsic resistance to antimicrobials has
traditionally been attributed to reduced permeability of the cell
envelope, presence of inactivating enzymes or eﬄux pumps
that can extrude the antimicrobial agents (Cox and Wright,
2013). Clinical use of potentiators have been applied successfully
to the antimicrobial class of β-lactams, where β-lactamase
inhibitors can significantly enhance the efficacy of β-lactams
(Drawz and Bonomo, 2010). An analogous approach has been
pursued by limiting the active eﬄux of antimicrobial agents
by eﬄux pump inhibitors (Lomovskaya and Bostian, 2006),
which have been shown to potentiate the efficacy of, e.g.,
levofloxacin in Pseudomonas aeruginosa (Renau et al., 1999)
and norfloxacin in Staphylococcus aureus (Stermitz et al., 2000).
However, eﬄux pumps inhibitors have not yet been approved
for treatment of human infections due to tolerability issues
(Fernebro, 2011).
It has recently been established from genome-wide studies of
intrinsic resistance determinants in the Gram-negative bacteria
Escherichia coli (Tamae et al., 2008; Liu et al., 2010), Acinetobacter
baylyi (Gomez and Neyfakh, 2006) and Pseudomonas aeruginosa
(Fajardo et al., 2008; Dötsch et al., 2009; Alvarez-Ortega et al.,
2010; Gallagher et al., 2011; Krahn et al., 2012) that large and
complex networks of both established and yet uncharacterized
gene products contribute to reduce the inhibitory activity of
antimicrobial agents. Equivalent comprehensive genome-wide
studies of intrinsic resistance determinants in Gram-positive
bacteria have not been performed, except for a single study that
determined the intrinsic resistance of S. aureus to vancomycin,
nisin and daptomycin (Blake and O’Neill, 2013). Staphylococcus
aureus is an opportunistic pathogen with the capability to
cause a wide range of diseases, ranging from systemic to
skin infections (Lowy, 1998). The ability to treat S. aureus
infections has been greatly hampered by the ability of this
pathogen to develop resistance to antimicrobials (Sakoulas
and Moellering, 2008; Chambers and DeLeo, 2009), which
necessitates an understanding of determinants that contribute
to the reduced susceptibility of S. aureus to antimicrobial
agents.
In the present study, we identified genetic determinants
contributing to the intrinsic resistance of S. aureus to eight
different antimicrobials (ciprofloxacin, oxacillin, linezolid,
fosfomycin, daptomycin, mupirocin, vancomycin, and
gentamicin). We employed the Nebraska Transposon Mutant
Library of 1920 single-gene inactivations in S. aureus JE2
(Fey et al., 2013) to screen for mutants that were unable to
grow at sub-inhibitory concentrations of the antimicrobials.
We identified multiple genes not previously recognized
as modulators of antibacterial sensitivity, thus providing
novel targets for the development of antibacterial sensitizer
compounds.
MATERIALS AND METHODS
Bacterial Strains, Growth Conditions and
Chemicals
The strains used in the study include S. aureus JE2 (plasmid-
cured derivative of USA300 LAC) and all derivative
strains within the Nebraska Transposon Mutant Library
(NTML), consisting of 1920 unique transposon mutants
with inactivation of non-essential genes (Fey et al., 2013).
The bursa aurealis transposon used to create the collection
contains the resistance cassette ermB conferring resistance
to erythromycin (Fey et al., 2013). All bacterial strains
were cultured at 37◦C in tryptic soy broth (TSB) or
on tryptic soy agar (TSA), with antimicrobial agents
added as indicated. Antimicrobial agents used in the
study were erythromycin (Sigma), ciprofloxacin (Sigma),
oxacillin (Sigma), linezolid (Sigma), fosfomycin (Sigma),
daptomycin (Santa Cruz Biotechnology), mupirocin
(Sigma), vancomycin (Sigma) and gentamicin (Sigma).
Transduction of atpA::8N6 into wild type (WT) JE2
was performed with bacteriophage ϕ11, by selecting for
transductants on erythromycin plates (5 µg/ml) (Fey et al.,
2013).
Screening for Increased Antimicrobial
Susceptibility
To screen for increased susceptibility among the NTML
strains, we first determined the minimum inhibitory
concentration (MIC) of WT strain JE2 to ciprofloxacin,
oxacillin, linezolid, fosfomycin, daptomycin, mupirocin,
vancomycin, and gentamicin. MIC was determined using a
twofold microbroth dilution assay according to Clinical and
Laboratory Standards Institute (CLSI) guidelines (CLSI, 2009),
except that cation-adjusted Mueller Hinton broth was substituted
with TSB.
The NTML is stored in glycerol at −80◦C in 20 96-well
microtiter plates. Material from the frozen stock was transferred
directly with a Deutz 96 cryoreplicator (Duetz et al., 2000) from
the 96-wells microtiter plates onto TSA plates supplemented with
5 µg/ml erythromycin (to prevent the growth of contaminants
during the screen, as all the strains in the NTML are resistant to
erythromycin; Fey et al., 2013) and 0.5x MIC of the respective
antimicrobial agent. The plates were incubated at 37◦C for
24 h and visually inspected for lack of growth of individual
mutants.
Determination of MIC of
Hypersusceptible Mutants
The MIC was determined for all strains displaying growth
deficiency in the hypersusceptibility screen to the respective
antimicrobial agent and WT strain JE2 using E-tests
(bioMérieux) performed on TSA plates. No erythromycin
was supplemented to the plates during MIC determination with
E-tests. The MIC was determined upon incubation at 37◦C
for 22 h and interpreted according to the guidelines of the
manufacturer.
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Treatment of Galleria mellonella With
Gentamicin
To investigate if increased antimicrobial susceptibility could be
detected in vivo, we employed the Galleria mellonella infection
model (Desbois and Coote, 2011; Ramarao et al., 2012). Healthy
5th-instar wax moth larvae weighting approximately 250 mg were
randomly picked from a batch purchased at a local pet store
and divided into six groups with 20 larvae in each. Virulence of
S. aureus WT and the atpA mutant were compared by injecting
20 larvae with 10 µl (containing 1 × 107 CFU) with a Hamilton
syringe into the hemocoel through the lowest left proleg. Survival
of G. mellonella was monitored for 120 h. For treatment efficacy
of gentamicin against S. aureus, 20 larvae for each group were
injected with 1 × 107 CFU of WT or the atpA mutant. One hour
post infection, the larvae were injected with 10 µl gentamicin
(1 mg/kg bodyweight) in the lowest right proleg. Gentamicin
therapy was repeated every 24 h for a total of 72 h and survival
of G. mellonella was monitored for 120 h. A control group
for toxicity of gentamicin (1 mg/kg bodyweight) as well as for
non-treated (inoculated with phosphate-buffered saline) were
included. The data was analyzed in GraphPad Prism 4 (GraphPad
Software Inc.) using the Kaplan–Meier method and statistical
difference determined using log rank test.
Chromosomal Reconstruction of the
atpA Mutant
Chromosomal reconstruction of the atpA mutant was
achieved by use of the temperature-sensitive shuttle
vector pBASE6 (Geiger et al., 2012). A chromosomal
region encompassing atpA was PCR amplified from WT
S. aureus JE2 chromosomal DNA using primer pair: 5′-
ATATGAGCTCGAAGAGTTAGATAAGATTGTCAAACTAG-
3′/5′-GATACAAGATCTGATGGTTTGTATTGCTACTTGC-3′
and cloned into pBASE6 via SacI/BglII. This plasmid was
purified from E. coli IM08B (Monk et al., 2015) and transformed
directly into JE2 atpA::8N6 (NE592) at 30◦C followed by
chromosomal integration by plating on TSA (10 µg/ml
chloramphenicol) at 44◦C overnight. Plasmid cross-out was
performed by passage at 30◦C followed by plating on TSA
(500 ng/ml anhydrotetracycline) and successful allelic exchange
of the transposon insertion with the intact atpA gene was selected
for by replica plating of colonies and screening for sensitivity
toward erythromycin and chloramphenicol. Reconstruction of
the atpA locus was verified by PCR amplification using primers
5′-CAAGTATGCTAAAGCATTATTTGACGTGTC-3′/5′-
CGTAATTTCTGCTTGTCTCGCTCTG-3′ positioned outside
the chromosomal region used for homologous recombination.
RESULTS AND DISCUSSION
Screening for Hyper-Susceptibility to
Antimicrobial Agents
The complete NTML of 1920 single-gene inactivations (Fey
et al., 2013) was screened for mutants displaying increased
susceptibility to eight antimicrobial agents with different
mechanism of action, by inspecting for lack of growth on
agar plates supplemented with 0.5x MIC of the respective
antimicrobials. The antimicrobials tested were ciprofloxacin,
oxacillin, linezolid, fosfomycin, daptomycin, mupirocin,
vancomycin, and gentamicin (Table 1). For the mutants
identified in the initial screen as being unable to grow at 0.5x
MIC, the MIC was determined using E-tests. A total of 68
mutants were confirmed to display twofold or greater increase
in susceptibility to one or more antimicrobial agents compared
to the WT strain S. aureus JE2 (Figure 1). Eight of these strains
displayed increased sensitivity to multiple agents.
Inactivation of Acquired Resistance
Genes Increase Susceptibility to
Oxacillin and Fosfomycin
The S. aureus JE2 strain carries the acquired resistance genes
mecA and fosB on the chromosome (Fey et al., 2013), which
confer resistance to β-lactams (Zapun et al., 2008) and fosfomycin
(Thompson et al., 2014), respectively. As a verification of
the screen, we indeed identified the mecA and fosB mutants
as more susceptible to oxacillin and fosfomycin, respectively
(Figure 1). In our experimental setup the MIC values of oxacillin
and fosfomycin for WT were within the susceptibility range
according to CLSI (CLSI, 2009), even though they possess
mecA and fosB. Choice of medium and NaCl concentration
may affect the absolute MIC value for oxacillin (Huang et al.,
1993) and discrepancies in absolute fosfomycin MIC between
E-test and liquid assays has been reported (Díez-Aguilar et al.,
2013; Mihailescu et al., 2014). Additionally, S. aureus JE2 is
resistant to ciprofloxacin due to mutations in the essential
topoisomerase genes gyrA and grlA (Sreedharan et al., 1990;
Ferrero et al., 1995; Diep et al., 2006; Highlander et al., 2007;
Kennedy et al., 2008). The lowering in MIC for these three
antimicrobials is potentially related to the effect of the resistance
genes or resistance mutations and may not necessarily classify
as intrinsic resistance determinants. S. aureus JE2 is susceptible
toward the remaining antimicrobials and the inactivations of
genes conferring increased susceptibility are considered intrinsic
resistance determinants.
Gentamicin
Gentamicin belongs to the bactericidal antibiotic class of
aminoglycosides, which interferes with protein synthesis through
binding to the 16S rRNA of the 30S small ribosomal unit causing
mistranslation of proteins (Shakil et al., 2008). Aminoglycosides
are polycationic compounds, which is an important feature
for their cell interactions and uptake (Shakil et al., 2008).
Twenty six mutants displayed increased sensitivity to gentamicin
(Figure 1). Inactivation of the gene rpsT encoding 30S ribosomal
protein S20 was found to render the cell more susceptible to
gentamicin suggesting that alteration of the ribosome assembly
can influence gentamicin sensitivity through some currently
unknown mechanism.
Six mutants with annotated membrane transport proteins
exhibited increased sensitivity to gentamicin, with the most
profound effect on sensitivity observed for vraG and trkA,
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TABLE 1 | Antimicrobial agents used in the screening for intrinsic resistance determinants, as well as the primary target and process affected by the
respective agents.
Antimicrobial Primary target Process affected JE2 MIC (µg/ml)
Ciprofloxacin DNA gyrase DNA replication 32
Oxacillin Transpeptidase Cell wall synthesis 0.5
Linezolid 50S rRNA subunit Protein synthesis 3
Fosfomycin MurA Cell wall synthesis 0.75
Daptomycin Cytoplasmic membrane Membrane permeability 0.19
Mupirocin Isoleucyl t-RNA Protein synthesis 0.125
Vancomycin NAM/NAG peptides Cell wall synthesis 1.5
Gentamicin 30S rRNA subunit Protein synthesis 1.5
The MIC (µg/ml) of wild type strain JE2 is displayed for each agent.
displaying sixfold reductions in MIC. Gentamicin uptake
into the cell is known to be dependent on membrane
potential, where hyperpolarization of the membrane leads
to increased uptake, while depolarization reduces the uptake
of gentamicin (Taber et al., 1987). Hyperpolarization and
accordingly increased gentamicin uptake is suspected for the
trkA mutant, as a trkA deletion mutant in Mycobacterium
smegmatis displays hyperpolarization and increased susceptibility
to aminoglycosides (Castañeda-García et al., 2011). Lack of the
TrkA transporter also potentiates the efficacy of aminoglycosides
in Pseudomonas aeruginosa (Lee et al., 2009; Gallagher et al.,
2011). Inactivation of vraG has previously been shown to increase
the susceptibility toward gentamicin, vancomycin and cationic
antimicrobial peptides in S. aureus, potentially by alteration of
the cell surface charge (Meehl et al., 2007; Yang et al., 2012). The
greatest sensitization for gentamicin, being a 16-fold reduction
in MIC, was observed upon inactivation of genes encoding
for subunits of the ATP synthase, namely atpA, atpB, atpG
and atpH. Transduction of atpA into WT JE2, confirmed that
transposon inactivation of atpA increases sensitivity of S. aureus
toward gentamicin. Inactivation of atpA also potentiated efficacy
of gentamicin in E. coli, which was hypothesized to occur via
increased uptake of aminoglycosides due to elevated membrane
potentials arising from altered respiration (Lobritz et al., 2015).
While we were unable to complement the atpA-inactivated
mutant with a functional atpA gene on a plasmid, we successfully
performed allelic exchange of the transposon insertion with
the intact atpA gene, generating a strain displaying gentamicin
sensitivity as WT (1.5 µg/ml).
Besides the numerous established genes modulating
gentamicin sensitivity, the NTML screen identified several
novel genes of unknown function contributing to the intrinsic
sensitivity to gentamicin (Figure 1).
Ciprofloxacin
Ciprofloxacin is a fluoroquinolone interfering with bacterial
replication via inhibition of the enzymes DNA gyrase and
topoisomerase IV (Blondeau, 2004). DNA gyrase, composed
of two subunits GyrA and GyrB, is essential for replication
initiation as the enzyme introduces negative supercoils ahead of
the replication fork (Drlica and Zhao, 1997), while topoisomerase
IV, composed of GrlA and GrlB, is responsible for decatenation of
the replicated daughter chromosomes (Drlica and Zhao, 1997).
Interaction of ciprofloxacin with these enzymes leads to a halt
in replication and ultimately to DNA strands breakage (Drlica
and Zhao, 1997; Blondeau, 2004). S. aureus JE2 is resistant to
ciprofloxacin, due to amino acid changes in the DNA gyrase GyrA
(Ser84Leu) and topoisomerase IV GrlA (Ser80Tyr), encoded by
gyrA and grlA respectively (Sreedharan et al., 1990; Ferrero et al.,
1995).
Elucidation of the intrinsic resistome in E. coli revealed
that multiple gene products related to DNA replication and
repair aid this bacterium to survive DNA damage generated
by fluoroquinolone treatment (Tamae et al., 2008; Liu et al.,
2010). Four of the 13 identified mutants in our screen with
increased sensitivity to ciprofloxacin also display inactivation of
genes related to DNA replication and repair, namely recG, xerC,
recX and xseA (Figure 1). The RecG protein is a DNA helicase
and strains with deletion of recG display reduced recombination
and DNA repair (Al-Deib et al., 1996). Identification of
recG corroborates previous work in S. aureus on increased
susceptibility to quinolones in a recG mutant (Niga et al., 1997).
A mutant of xseA, encoding the large subunit of exonuclease VII,
was also observed in E. coli to be hypersensitive to ciprofloxacin
(Tamae et al., 2008).
Three mutants with inactivated membrane transport systems,
norA, trkA and SAUSA300_0924, are at least fourfold more
sensitive to ciprofloxacin than the WT strain. This might
be due to decreased eﬄux of this agent, as ciprofloxacin
has been observed to being subjected to cellular eﬄux by
pump activity of multiple eﬄux systems, e.g., NorA (Yamada
et al., 1997; Muñoz-Bellido et al., 1999). Moreover, it was
confirmed that inactivation of the stress response sigma factor
σB encoded by rpoF and the σB activator RsbU potentiated
the effect of ciprofloxacin, which is in agreement with previous
observations in S. aureus (Riordan et al., 2006). We also
identified the clpP gene encoding the proteolytic subunit of
the ClpXP two-component protease to be more susceptible to
ciprofloxacin, corroborating a study in P. aeruginosa (Fernández
et al., 2012). A possible link between clpP and ciprofloxacin
susceptibility is that clpP has been shown to interfere with
activation of the SOS DNA-damage response (Cohn et al.,
2011). Additionally, inactivation of several hypothetical genes
(SAUSA300_1789 and SAUSA300_2311) also conferred a fourfold
or greater sensitization to ciprofloxacin relative to the WT
strain.
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FIGURE 1 | Gene inactivations affecting susceptibility to antimicrobial agents to one or more of the eight antimicrobial agents tested. The effect on
susceptibility is displayed using a gray scale indicating fold reductions in sensitivity: [2;4] , [4;8] and [8;16] . The genes are divided into the categories: (1) Membrane
transporters, (2) Metabolism, (3) Replication and DNA repair, (4) Pro-phage encoded genes, (5) Protein synthesis, (6) Transcriptional regulators, chaperones, cell wall
and membrane stress mechanisms and (7) Unassigned and hypothetical genes. CIP (Ciprofloxacin), OXA (Oxacillin), LZD (Linezolid), FOF (Fosfomycin), DAP
(Daptomycin), MUP (Mupirocin), VAN (Vancomycin) and GEN (Gentamicin).
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Linezolid
Linezolid belongs to the antimicrobial class of oxazolidinones
(Moellering, 2003). Linezolid interacts with the A-site of the
50S ribosomal subunit and inhibits formation of the initiation
complex, thus inhibiting protein synthesis (Wilson, 2014).
A total of 15 mutants were more susceptible to linezolid
(Figure 1), with six mutants displaying at least a fourfold
increased sensitivity. None of the identified genes have to our
knowledge previously been associated with increased linezolid
susceptibility. Interestingly, these genes exert widely different
functions, such as zapA encoding the divisome protein ZapA,
which stabilizes Z-ring formation (Adams and Errington, 2009),
mutS2 encoding MutS2 that in Helicobacter pylori function
as an inhibitor of recombination (Pinto et al., 2005) and the
ribonuclease R.
Mupirocin
The target of mupirocin is the isoleucyl-tRNA synthetase
(IleRS), thus inhibiting aminoacylation of isoleucine to
the cognate tRNA and thereby prevents protein synthesis
(Yanagisawa et al., 1994; Pope et al., 1998). Only three mutants
exhibited increased sensitivity toward mupirocin (Figure 1).
None of the mutants, sucD, gpmI and SAUSA300_2299,
have previously been associated with altered susceptibility to
mupirocin. The gene SAUSA300_2299 has been annotated
as a putative multidrug resistance transporter and could
be involved in active eﬄux of mupirocin from the
cytoplasm.
Oxacillin
Oxacillin is a β-lactam interfering with cell wall biosynthesis.
The bactericidal activity of oxacillin derives from its binding
to penicillin-binding proteins (PBPs), thus preventing cross-
linking of peptidoglycan units of the cell wall, which eventually
causes cell lysis (Kotra and Mobashery, 1998). In our study,
we identified 13 genes displaying increased susceptibility to
oxacillin (Figure 1). S. aureus JE2 contains the mecA gene
encoding the alternative penicillin binding protein 2a (PBP2a)
that enables cross-linking of peptidoglycan units in the presence
of β-lactams (Zapun et al., 2008). Indeed inactivation of mecA
rendered the strain more susceptible to oxacillin. A functional
σB response is important for oxacillin susceptibility (Singh
et al., 2003; Schulthess et al., 2009) and RsbU together with
RsbV are activators of this stress response (Palma and Cheung,
2001), both of these determinants were confirmed as targets for
oxacillin sensitizers in our screen. In addition to the previously
established contributors to oxacillin intrinsic resistance, several
genes of unknown function were identified (SAUSA300_1792 and
SAUSA300_2297) that upon inactivation increased susceptibility
to oxacillin equally well as mecA inactivation. It was also observed
that inactivation of the unknown gene SAUSA300_1003 displayed
even greater sensitivity to oxacillin than the mecA mutant.
Moreover, this SAUSA300_1003 mutant displayed increased
sensitivity to ciprofloxacin, linezolid and daptomycin and thereby
it could be of interest to investigate how this gene can potentiate
the efficacy of multiple antimicrobial agents.
Fosfomycin
Fosfomycin is a phosphoenolpyruvate analog that inhibits
the first enzymatic step in peptidoglycan biosynthesis, by
binding to the enzyme MurA and thereby prevent the
formation of N-acetylmuramic acid, an essential precursor
of the peptidoglycan cell wall (Michalopoulos et al., 2011;
Karageorgopoulos et al., 2012). S. aureus JE2 harbors the
fosfomycin resistance gene (fosB) that chemically inactivates
fosfomycin (Rigsby et al., 2005; Castañeda-García et al.,
2013) and in agreement, the fosB mutant showed increased
sensitivity to fosfomycin. Moreover, inactivation of the gene
SAUSA300_2279 encoding a regulatory protein of the LysR
family also increased susceptibility to fosfomycin. This gene
is located directly upstream of fosB and could potentially
be a positive regulator of fosB or the transposon insertion
in SAUSA300_2279 could prevent proper transcription of
fosB. Four other genes also affected fosfomycin susceptibility,
with a hypothetical (SAUSA300_0553) and a putative peptide
transporter (SAUSA300_0073) being most prominent with
threefold greater sensitivity to fosfomycin, which equal the
potentiating effect of the fosB mutant.
Vancomycin
Vancomycin is a glycopeptide antibiotic readily used in
the treatment of methicillin-resistant S. aureus (Liu et al.,
2011). The bactericidal activity of vancomycin is derived
from the inhibition of cell wall biosynthesis. Vancomycin
binds to the D-Ala-D-Ala residues of the pentapeptides
on the peptidoglycan precursors N-acetylmuramic acid and
N-acetylglucosamine and thus prevents peptide cross-linking
of the polysaccharide backbone in peptidoglycan biosynthesis
(Reynolds, 1989; Boger, 2001). Inactivation of two genes
increased the susceptibility to vancomycin, with a maximum two-
fold reduction in MIC (Figure 1). We confirmed the previously
established vancomycin intrinsic resistance determinants vraS
(Kuroda et al., 2003; Gardete et al., 2012) and vraF of
the VraFG ABC transporter system (Meehl et al., 2007).
Although our screen identified recognized vancomycin intrinsic
resistance determinants, we did not observe mutants of the
dlt operon as seen previously in a corresponding vancomycin
hypersusceptibility screen (Blake and O’Neill, 2013). No
strains in the NTML exist with inactivation of any of the
four genes in the dlt operon, which is involved in adding
positively charged D-alanine to teichoic acids (Peschel et al.,
1999).
Daptomycin
Daptomycin is a cyclic lipopeptide displaying bactericidal activity
against many Gram-positive organisms (Steenbergen et al., 2005).
The bactericidal activity of daptomycin is attributed to the
insertion of the lipophilic tail into the bacterial cell membrane,
leading to rapid membrane depolarization and potassium ion
eﬄux, with downstream arrest of DNA, RNA and protein
synthesis (Steenbergen et al., 2005).
Only a single mutant, SAUSA300_1003, displayed increased
susceptibility to daptomycin. The gene SAUSA300_1003 encodes
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FIGURE 2 | Effect of gentamicin treatment of G. mellonella larvae
inoculated with 1 × 107 CFU of S. aureus JE2 and the atpA mutant.
Gentamicin (1 mg/kg bodyweight) were administered 1 h post infection with
follow-up treatments at 24, 48, and 72 h. Prolonged survival of G. mellonella
inoculated with atpA due to gentamicin treatment was observed. All larvae
survived treatment with only gentamicin (1 mg/kg bodyweight).
a protein of unknown function and this mutant is also more
susceptible to several of the other antimicrobial agents tested.
Potentiating the Effect of Gentamicin in
the Galleria mellonella Infection Model
To verify the potential of enhancing the efficacy of antimicrobial
agents by targeting a non-essential gene product in S. aureus,
we employed the G. mellonella infection model (Ramarao et al.,
2012). We tested the efficacy of gentamicin at a clinically
relevant dose (1 mg/kg bodyweight) to promote survival of
G. mellonella infected with a lethal dose (107 cells/larvae) of
S. aureus JE2 (WT) and the atpA mutant (Figure 2). Gentamicin
significantly prolonged survival of G. mellonella infected with the
atpA mutant compared to the treatment of WT (P < 0.0001).
None of G. mellonella larvae in the group only receiving
gentamicin treatment died during the experiment (Data not
shown).
CONCLUSION
In this work, we have identified genetic determinants that
increase the sensitivity of S. aureus to eight antimicrobial agents.
The many modulators of antimicrobial susceptibility uncovered
here for S. aureus JE2 comprise both previously established
determinants in addition to numerous novel genes. To our
knowledge this study provides the first whole genome overview
of intrinsic resistance genes of S. aureus to agents with different
modes of action. With the results obtained, it will be feasible
to select particular genes for further investigation as targets
for antimicrobial potentiators. The mechanisms by which the
majority of these determinants contribute to modulate antibiotic
susceptibility remain unknown and further work is required to
establish this.
It is important to note that S. aureus JE2 carries resistance
determinants to oxacillin and fosfomycin as well as mutations
conferring resistance to ciprofloxacin and the genes identified
for these agents cannot per se be classified as intrinsic resistance
genes, unless gene inactivation is examined in a susceptible strain.
However, the gene inactivations identified here to reduce the MIC
of these agents could potentially be explored for re-sensitizing
resistant S. aureus isolates.
Staphylococcus aureus JE2 was not phenotypically resistant
to the remaining antibiotics tested (linezolid, vancomycin,
gentamicin, daptomycin and mupirocin). However, an
antimicrobial agent such as gentamicin has limited use against
S. aureus due to the risk of toxicity at the required clinical
concentrations (Rayner and Munckhof, 2005). Therefore, based
on our results co-administration of an inhibitor targeting the
ATP synthase could potentially lower the concentration of
gentamicin needed for treatment of S. aureus and thus increase
the usefulness of this drug. In the G. mellonella infection model
we observed significantly increased survival of larvae infected
with atpA compared to WT, when treated with gentamicin at
similar concentrations used for human therapy (Rayner and
Munckhof, 2005).
Improved activity of vancomycin could also be of clinical
significance, even for strains that are already susceptible to
this agent. There is an inverted association between MIC and
treatment efficiency of vancomycin against methicillin-resistant
S. aureus infections, even with MIC values well within the
susceptibility range (Sakoulas et al., 2004; Lodise et al., 2008).
A further reduction of the vancomycin MIC with a helper-drug
could thus increase the probability of vancomycin treatment
success.
Taken together, our observations provide a framework for
understanding the contribution of chromosomal determinants
that affect the susceptibility to antimicrobial agents in S. aureus
and provide novel targets for further exploration in development
of small molecules to be used as antimicrobial potentiators.
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